MedTrace Logo

Schistosoma Mansoni Morbidity in Children Aged 1-5 Years

NCT01901484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2014-09-17

No results posted yet for this study

Summary

This study is about intestinal schistosomiasis, commonly known as bilharzia, in children aged 1-5 years along Lake Victoria shoreline.The children will be screened for S. mansoni and the effects of the disease will be assessed.Children found positive with S. mansoni will be treated with praziquantel and followed up for a year.

Conditions

  • Intestinal Schistosomiasis

Interventions

DRUG

Praziquantel

All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Allen Nalugwa, PhD · CHDC-Makerere University

  • Annette Olsen, PhD · University of Copenhagen

  • Edridah Muheki, PhD · Ministry of Health, Vector Control Division

  • Fred Nuwaha, PhD · School of Public Health, Makerere University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01901484 on ClinicalTrials.gov